Ardelyx offers high-risk, high-upside biotech growth as IBSRELA scales toward blockbuster status while XPHOZAH navigates Medicare bundling pressure.
Overview
Ardelyx is a commercial-stage biopharma built around tenapanor, a minimally absorbed oral therapy targeting NHE3 in the GI tract. Its two marketed products, IBSRELA and XPHOZAH, address IBS-C and dialysis-related hyperphosphatemia with differentiated mechanisms versus existing standards of care. U.S. product sales drive the business, supplemented by international licensing and royalties. The thesis rests on IBSRELA’s rapid growth, XPHOZAH’s disruptive lower-pill-burden profile, and long-term patent protection supporting a path toward profitability.